Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Arena Pharmaceuticals divulges novel GRP119 receptor agonists

Nov. 26, 2012

Study of alpha-1-antitrypsin drug shows efficacy and safety in type 1 diabetes

Nov. 23, 2012

GSK-1292263 markedly reduces lipids in nondiabetic subjects

Nov. 23, 2012

Niacin analogue ARI-3037-MO evaluated in healthy subjects

Nov. 23, 2012

Researchers at Pfizer present new acetyl-CoA carboxylase inhibitors

Nov. 22, 2012

Scientists at Daiichi Sankyo prepare new 11-beta-HSD1 inhibitors

Nov. 22, 2012

Antisense oligonucleotide drug targets alpha-1-antitrypsin deficiency

Nov. 22, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

Bristol-Myers Squibb gains option rights for Biocon drug

Nov. 19, 2012

AstraZeneca will not exercise the option to acquire diabetes assets from Prosidion

Nov. 16, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....